申请人:Revolution Medicines, Inc.
公开号:US20200197391A1
公开(公告)日:2020-06-25
The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.